Technological limitations, not biology, could be the cause of perceived high rates of breast tumor growth in younger women.
Technological limitations, not biology, could be the cause of perceived high rates of breast tumor growth in younger women. Previously, poor mammography screening outcomes for women aged 40 to 49 were pinned on faster tumor growth and reduced tumor detectability, but a new study shows the latter is the major culprit.
A breast cancer screening computer simulation model was developed for the study to estimate how biology and technology affect mammography sensitivity. The researchers calibrated the predicted breast cancer incidence rates to the actual rates from the Surveillance, Epidemiology, and End Results database. They compared distributions of screen-detected tumor sizes to the actual distributions obtained from the Breast Cancer Surveillance Consortium to estimate relative impact of lower tumor detectability and tumor volume doubling time on the younger women's screening outcomes.
The lowered ability to detect tumors accounted for 79% of the poorer sensitivity in the model, according to the research, which was published in the Journal of the National Cancer Institute. The remaining 21% was due to faster tumor growth (doi:10.1093/jnci/djq271).
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.